IBRX

ImmunityBio, Inc.

5 catalysts on file

IBRX

ImmunityBio, Inc.

AdCom Confirmed

ANKTIVA

non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS)

253d ago Dec 11, 2025

SEC 8-K verified 2mo ago

IBRX

ImmunityBio, Inc.

Approval Confirmed

ANKTIVA

non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS)

232d ago Jan 1, 2026

SEC 8-K verified 2mo ago

IBRX

ImmunityBio, Inc.

Phase 2 Estimated

Long COVID

T-minus 71 days ~ Oct 31, 2026

ClinicalTrials.gov verified 2mo ago

IBRX

ImmunityBio, Inc.

Phase 2 Estimated

Gemcitabine

Platinum-resistant Ovarian Cancer

T-minus 283 days ~ May 31, 2027

ClinicalTrials.gov verified 2mo ago

IBRX

ImmunityBio, Inc.

Phase 2 AI-extracted

ANKTIVA

non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS)

Date TBD Date TBD

SEC 8-K verified 2mo ago